
SK bioscience and GSK start trial of Covid-19 vaccine
SK bioscience (SK) and GlaxoSmithKline (GSK) have initiated a Phase III clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase I/II results. The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to… Read More














